Alumis (ALMS) Non-Current Deffered Revenue (2025)

Alumis' (ALMS) quarterly Non-Current Deffered Revenue came in at $2.6 million in Q4 2025, up 34.31% on a QoQ basis from $1.9 million in Q3 2025.

Alumis (ALMS) Non-Current Deffered Revenue (2025) Analysis & Trends

Alumis (ALMS) has 1 years of Non-Current Deffered Revenue data on file, last reported at $2.6 million in Q4 2025.

On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $2.6 million in Q4 2025; TTM through Dec 2025 was $2.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.6 million, changed N/A from the prior year.
Non-Current Deffered Revenue for Q4 2025 stood at $2.6 million, up from $1.9 million in the prior quarter.
Over the last five years, Non-Current Deffered Revenue for ALMS reached as high as $2.6 million in Q2 2025 and fell as low as $1.9 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	225.10 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Alumis	2.41 Bn	2.10 Bn	-	2.61 Mn

Download Data